Previous Article | Next Article 
Molecular and Cellular Biology, February 1999, p. 1101-1115, Vol. 19, No. 2
Department of Cell Signaling, DNAX Research
Institute, Palo Alto, California 94304-1104
Received 17 April 1998/Returned for modification 15 June
1998/Accepted 2 November 1998
Ras-activated signal transduction pathways are implicated in the
control of cell proliferation, differentiation, apoptosis, and
tumorigenesis, but the molecular mechanisms mediating these diverse
functions have yet to be fully elucidated. Conditionally active forms
of Raf, v-Src, and MEK1 were used to identify changes in gene
expression that participate in oncogenic transformation, as well as in
normal growth control. Activation of Raf, v-Src, and MEK1 led to
induced expression of c-Myc and cyclin D1. Induction of c-Myc mRNA by
Raf was an immediate-early response, whereas the induction of cyclin D1
mRNA was delayed and inhibited by cycloheximide. Raf activation also
resulted in the induction of an established c-Myc target gene,
ornithine decarboxylase (ODC). ODC induction by Raf was mediated, in
part, by tandem E-boxes contained in the first intron of the gene.
Activation of the human colony-stimulating factor 1 (CSF-1) receptor in
NIH 3T3 cells leads to activation of the mitogen-activated protein
(MAP) kinase pathway and induced expression of c-Fos, c-Myc, and cyclin
D1, leading to a potent mitogenic response. By contrast, a mutated form
of this receptor fails to activate the MAP kinases or induce c-Myc and
cyclin D1 expression and fails to elicit a mitogenic response. The
biological significance of c-Myc and cyclin D1 induction by Raf and
v-Src was confirmed by the demonstration that both of these protein kinases complemented the signaling and mitogenic defects of cells expressing this mutated form of the human CSF-1 receptor. Furthermore, the induction of c-Myc and cyclin D1 by oncogenes and growth factors was inhibited by PD098059, a specific MAP kinase kinase (MEK) inhibitor. These data suggest that the Raf/MEK/MAP kinase pathway plays
an important role in the regulation of c-Myc and cyclin D1 expression
in NIH 3T3 cells. The ability of oncogenes such as Raf and v-Src to
regulate the expression of these proteins reveals new lines of
communication between cytosolic signal transducers and the cell cycle machinery.
The Ras-activated mitogen-activated
protein (MAP) kinase signaling pathway participates in the control of a
variety of biological processes, including cell proliferation,
migration, differentiation, and apoptosis. The importance of this
pathway in metazoan development is emphasized by the fact that
loss-of-function mutations of components of this pathway have severe
consequences on development. Moreover, constitutively activated forms
of Ras proteins are found in approximately 35% of all human cancers
(13, 36, 49, 60, 63, 132).
Cycling of the Ras family of membrane-bound GTPases between
GTP-bound (active) and GDP-bound (inactive) states is regulated by guanine nucleotide exchange factors and GTPase-activating proteins (25). GTP-bound Ras recruits a variety of proteins to the
plasma membrane, including Ral-GDS, Rin1, p120RasGAP, p110
PI3' kinase, and Raf (44, 46), many of which serve to
propagate the signal from activated Ras throughout the cell. Among the
best-characterized effectors of Ras are the Raf family of
serine-specific protein kinases, which play an important role in cell
proliferation, differentiation, and survival (19, 23, 62, 78, 112,
120, 122-124).
The three members of the Raf family of protein kinases, A-Raf, B-Raf,
and Raf-1, share similar structural features and are activated as a
consequence of the engagement of cell surface receptors by their
cognate ligands (114, 125). Although the precise mechanism of Raf-1 activation is not fully elucidated, the favored model suggests
that Raf-1 is recruited to the plasma membrane by direct binding to
activated Ras. Membrane associated Raf-1 is then believed to be
phosphorylated and thereby activated by members of the Src family of
protein tyrosine kinases which have pleiotropic effects on the control
of cell morphology, migration, and the cell cycle (29, 61, 65, 66,
74, 82, 93, 113, 117, 121, 126). However, there are indications
that additional mechanisms for Raf-1 regulation exist (74, 130,
135). Activated Raf-1, in turn, phosphorylates to activate MAP
kinase kinase (MEK), which in turn phosphorylates to activate p42 and
p44 MAP kinase, also known as ERK2 and ERK1, respectively (22, 32,
53, 92). Activated MAP kinases elicit pleiotropic effects on cell
function by phosphorylating a diverse array of cellular proteins,
including a number of transcription factors that influence patterns of
cellular gene expression (73, 77, 118).
Activated forms of Ras, Raf, and MEK can induce DNA synthesis and
cellular transformation in vitro, and dominant-interfering forms of Raf
and MEK can block Ras-induced mitogenesis and transformation (19,
24, 40, 50, 64, 103). In NIH 3T3 cells Raf is competent to induce
DNA synthesis at low levels of activation, whereas at higher levels of
activation it induces cell cycle arrest (128). To understand
the molecular basis of Raf-induced cell proliferation and oncogenic
transformation, we sought to identify changes in gene expression that
occur after Raf activation by using conditionally active forms of these
protein kinases ( Considerable evidence has implicated c-Myc and cyclin D1 as important
regulators of the mammalian cell cycle (5, 42, 54, 67, 136).
Activation of the transcription factor c-Myc in quiescent fibroblasts
induces cell cycle reentry, whereas inhibition of c-Myc function
results in cell cycle arrest (8, 9, 16, 57, 127). The D-type
cyclins are transcriptionally induced in the mid-G1 phase
of the cell cycle and partner with cyclin-dependent kinases (CDK4 and
CDK6) to elicit phosphorylation of the retinoblastoma (Rb) protein. Rb
phosphorylation leads to the release of the transcription factor E2F
that influences the expression of genes required for the progression of
cells into S phase (107). Both c-Myc and cyclin D1 have
oncogenic potential and are overexpressed in a variety of human cancers
(30, 35, 43, 76, 86, 104, 111).
In this study we demonstrate the induction of the genes encoding c-Myc
and cyclin D1 by the Raf/MEK/MAP kinase pathway in NIH 3T3 cells. The
functional significance of the induction of these genes is
substantiated by the apparent ability of Raf to complement a defective
form of the human CSF-1 receptor, which fails to induce DNA synthesis
in NIH 3T3 cells as a consequence of its inability to induce the
expression of c-Myc and cyclin D1. Furthermore, the ability of a
variety of growth factors and oncogenes to induce c-Myc and cyclin D1
is abrogated by a specific and selective inhibitor of MEK activation.
Finally, since Src-family protein tyrosine kinases have been implicated
in the regulation of c-Myc, we describe the ability of a conditionally
active form of v-Src that activates the MAP kinase pathway leading to
induced expression of c-Myc and cyclin D1, to complement the mitogenic defect of the mutated colony-stimulating factor 1 (CSF-1) receptor. These data suggest that, at least in NIH 3T3 cells, the Ras-activated MAP kinase pathway plays an important role in controlling the expression of these crucial cell cycle regulators.
Cell culture.
NIH 3T3 cells expressing Expression of Raf-1[DD]:ER, v-Src:ER, and
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Complementation of Defective Colony-Stimulating
Factor 1 Receptor Signaling and Mitogenesis by Raf and v-Src
ABSTRACT
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References
INTRODUCTION
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References
Raf:ER) (87, 100). Raf:ER proteins
are rapidly activated by the addition of estrogen or its analogues to
the cell culture medium, resulting in alterations in gene expression
that lead to oncogenic transformation (87, 100, 128).
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References
Raf-1:ER,
B-Raf:ER, and B-Raf:ER* have been described previously (87,
100, 128). Clonal populations of NIH 3T3 cells expressing either
the human CSF-1 receptor or a mutated version of this receptor
containing a tyrosine-to-phenylalanine mutation at amino acid 809 (CSF-1R[809F]) were a gift of Martine Roussel (97-99).
NIH 3T3 cells expressing Raf-1[DD]:ER and v-Src:ER were
generated by retroviral infection of the appropriate target cells as
described previously (14, 100). All cells were grown in
Dulbecco's modified Eagle medium (DMEM) containing 10% (vol/vol)
fetal calf serum (FCS) and rendered quiescent in either 0.5% (vol/vol)
FCS, deluxe serum-free medium (DSFM), or DSFM lacking insulin,
selenium, and transferrin (modified DSFM) (128). Cells expressing v-Src:ER were cultured in DMEM containing 10% (vol/vol) charcoal-stripped FCS (Gemini Bioproducts). Recombinant human CSF-1 was
a gift of Steve Clark (Genetics Institute). Raf:ER proteins were
activated with 4-hydroxytamoxifen (4-HT; Research Biochemicals International) or ICI 182,780 (gift of Alan Wakeling, Zeneca
Pharmaceuticals). Ethanol was used as a solvent control in all experiments.
MEK1:ER.
To construct conditionally active
Raf-1[DD]:ER, DNA sequences encoding full-length human
Raf-1 containing two activating point mutations (Y340D and Y341D; a
gift from Debbie Morrison) were fused to the hormone binding domain of
the HE14 allele of the human estrogen receptor (hbER) and cloned into
the pBabepuro3 retrovirus expression vector (14, 27, 72). To
generate v-Src:ER, DNA sequences encoding the Schmidt Ruppin A form of
v-Src (a gift from Josh Kaplan) were fused to hbER and cloned into the
pWZLblast3, pBabepuro3, or pLNCX retroviral expression vectors
(45, 100). In the case of pWZLblast3 (a gift from Jay
Morgenstern), expression of a bicistronic mRNA from the murine leukemia
virus long terminal repeat containing the encephalomyocarditis virus
internal ribosome entry site permits the expression of both v-Src:ER
and the blasticidin drug resistance gene (see Fig. 6A). To generate
MEK1:ER, DNA sequences encoding a constitutively active form of MEK1
containing an amino terminal deletion (N3) and two activating
mutations (S218E and S222D) (a gift from Natalie Ahn) (64)
were fused to hbER and cloned into the pBabepuro3 retroviral expression
vector. Raf-1[DD], v-Src, and MEK1 DNA sequences were
all amplified by PCR to introduce the appropriate restriction enzyme
sites for cloning (details available upon request).
MEK-1:ER by
Western blotting. A clonal population of MEK1:ER expressing cells
was isolated by ring cloning.
Western blotting and antibody detection.
Cell extracts were
prepared, quantitated, and blotted as described previously, except that
280 mM 
-mercaptoethanol was used as a reducing agent and lysates
were heated to 70°C prior to sodium dodecyl sulfate-polyacrylamide
gel electrophoresis. Antisera used in this study were raised against
c-Myc and phosphotyrosine (UBI, Inc.); p42 MAP kinase, p44 MAP kinase,
and the human estrogen receptor (Santa Cruz Biotechnology); and
phospho-ERK1/ERK2 (New England Biolabs). Anti-cyclin D1 antiserum was a
kind gift from David Parry. Antigen-antibody complexes were visualized
by using the enhanced chemiluminescence (ECL) detection system (Amersham).
Immune-complex kinase assays. MAP kinase activity was measured by an in vitro immunoprecipitation-kinase assay by using myelin basic protein (MBP) as a substrate as described previously (100).
RNase protections. RNase protections were conducted as described previously (68). A mouse c-Myc exon 1 riboprobe was prepared with a cDNA linearized with BamHI (a gift from Nissim Hay). This riboprobe protected a P1-initiated c-Myc transcript of approximately 400 bp and a P2-initiated transcript of approximately 350 bp. A mouse ornithine decarboxylase (ODC) cDNA (nucleotides 729 to 2357; a gift from Philip Coffino) was linearized with Eco47III, and the resulting riboprobe protected a fragment of approximately 517 bp. A full-length mouse cyclin D1 cDNA (a gift from Emma Lees) was linearized with SalI, and the resulting riboprobe protected a fragment of approximately 250 bp (nucleotides 826 to 1075). A riboprobe prepared from a plasmid containing a 120-bp fragment of human GAPDH was included in all of the hybridizations and used as a loading control. Ten micrograms of total RNA (RNeasy kit; Qiagen) or tRNA (as a negative control) were hybridized overnight at 45°C with both gene-specific and GAPDH riboprobes, treated with RNase A and RNase T1 to digest the single-stranded RNA, extracted with phenol, and ethanol precipitated, with the resulting protected fragments resolved by electrophoresis on 6% (wt/vol) acrylamide sequencing gels. Results were quantitated with a Molecular Dynamics Storm PhosphorImager.
Transient transfections.
Reporter constructs, comprising the
c-Myc, ODC, or cyclin D1 promoters linked to luciferase, were
transiently transfected into confluent monolayers of NIH 3T3 cells
cultured in 60-mm tissue culture dishes by using either
DNA-Lipofectamine complexes (Gibco-BRL) or the DEAE-dextran method
(69). The mouse c-Myc promoter-luciferase construct
(pGL2-myc, provided by Mike Ostrowski) was comprised of a 500-bp
PvuII-SstI fragment that included approximately
140 bp upstream and 360 bp downstream of the mouse c-Myc P2 promoter. The ODC promoter-luciferase constructs (ODCLuc or ODCLucS-5A) were provided by John Cleveland and were described previously (15). The mouse cyclin D1 promoter-luciferase construct
[mD1(-984)luc; provided by Gordon Peters] was comprised
of 984 bp of DNA located upstream of the transcription initiation site
of the mouse cyclin D1 gene. In all experiments the luciferase reporter
constructs were cotransfected with pSR
--Gal (provided by Naoko
Arai), which contains a constitutively active promoter linked to
sequences encoding -galactosidase as a control for transfection
efficiency (69). After transfection the cells were split
into the wells of a 24-well dish and allowed to adhere in DMEM
containing 10% (vol/vol) FCS for 3 h. The medium was then
replaced with DMEM containing 0.5% (vol/vol) FCS plus ethanol (solvent
control), 4-HT, or ICI 182,750. Cells were harvested 36 to 48 h
later in Reporter lysis buffer (Promega); luciferase activity was
measured by using the luciferase assay system (Promega), and
-galactosidase activity was measured by using the Galacto-Light kit
(Tropix) and quantitated with an AutoLumat LB953 luminometer (EG & G
Berthold). To control for transfection efficiency, all results are
expressed as the ratio of luciferase to -galactosidase activity. In
bar graphs, each bar represents the average of four samples (c-Myc experiments), three samples (cyclin D1 experiments), or six samples (ODC experiments), and error bars indicate standard deviations.
DNA synthesis assays. Cells were grown to confluence in 96-well microtiter dishes, held at confluence for 3 days, cultured for an additional 24 h in DSFM, and then treated with either 10% (vol/vol) FCS, 300 nM CSF-1, 4-HT, or 300 nM CSF-1 plus 4-HT. Then 1 µCi of [methyl-3H]thymidine was added to each well simultaneously with the addition of growth stimuli, and the cells were incubated for a further 36 h prior to harvest with a Skatron Cell Harvester as described previously (128). Each measurement was conducted in quadruplicate, and error bars indicate standard deviations. The absence of a visible error bar indicates that the standard deviation was too small to register on the graph at the scale used.
| |
RESULTS |
|---|
|
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References
|
|---|
Transcriptional regulation of c-Myc and cyclin D1 expression by
Raf.
To determine the effects of MAP kinase activation on the
expression of components of the cell cycle machinery, we explored the
consequences of Raf activation on the expression of c-Myc and cyclin
D1. RNA and protein samples were prepared from a pooled population of
NIH 3T3 cells expressing a conditionally active form of oncogenic B-Raf
(B-Raf:ER*) (87) that was rendered quiescent and then
treated with ICI 182,780 (ICI) to activate B-Raf:ER* for different
lengths of time as indicated (Fig. 1A). RNase protection analysis indicated that c-Myc mRNA was induced 4- to
15-fold after B-Raf:ER* activation, with kinetics and magnitude of
induction similar to those observed in response to serum stimulation (Fig. 1A and B) (37). In asynchronously growing NIH 3T3
cells, the basal level of c-Myc expression was significantly higher, such that c-Myc mRNA was induced only two- to threefold after Raf
activation (data not shown). Treatment of parental NIH 3T3 cells or
cells expressing a kinase-inactive form of Raf-1:ER (Raf301:ER)
with ICI or 4-HT had no effect on the levels of c-Myc mRNA, indicating
that the induction of c-Myc requires Raf kinase activity (data not
shown).
|
B-Raf:ER*
was mediated by an increase in c-Myc transcription, NIH 3T3 cells were
transiently transfected with a reporter construct (pGL2-myc) consisting
of a portion of the c-Myc promoter fused to luciferase. Activation of
B-Raf:ER* led to a ninefold induction of luciferase activity (Fig.
1C), indicating that Raf activation leads to transactivation of the
c-Myc promoter. The induction of c-Myc mRNA in response to serum
stimulation is immediate early in that it is resistant to the effects
of cycloheximide, an inhibitor of protein synthesis (47).
Similarly, activation of B-Raf:ER* or treatment of cells with
cycloheximide alone resulted in an increase in c-Myc mRNA levels (Fig.
2A, top panel). Activation of
B-Raf:ER* in the presence of cycloheximide led to superinduction of
c-Myc mRNA, indicating that c-Myc is an immediate-early transcriptional target of Raf activation.
|
B-Raf:ER*
resulted in a rapid induction of p62c-Myc that was readily
detected after 40 min and was sustained at elevated levels for at least
6 h (Fig. 1D).
We have previously shown that the activity of Raf:ER proteins can be
titrated by varying the concentration of 4-HT added to the cell culture
medium. Low levels of Raf activity (up to 2 nM 4-HT in
B-Raf:ER*-expressing cells) promote cell proliferation, and high
levels of Raf activity (
5 nM 4-HT) promote a G1
arrest that is mediated by p21Cip1 (128). To
investigate the expression of c-Myc in response to different
levels of Raf activation, we treated quiescent B-Raf:ER*-expressing cells with different concentrations of 4-HT for 4.5 h and examined MAP kinase activation and c-Myc expression (Fig. 1E). Both
p62c-Myc expression and MAP kinase activity were maximal at
concentrations of 4-HT greater than 2 nM, with higher concentrations of
4-HT having no additional effect on MAP kinase activity or the level of
p62c-Myc expression.
Cells transformed by activated Ras express elevated levels of cyclin
D1, and previously we have demonstrated that activation of Raf-1:ER
leads to induced cyclin D1 expression (58, 128). We
therefore investigated the induction of cyclin D1 mRNA by Raf. Activation of B-Raf:ER* led to a sustained induction of cyclin D1
mRNA, which was maximal between 5 and 7 h after B-Raf:ER* activation (Fig. 2A, middle panel). Such induction kinetics are consistent with the regulation of cyclin D1 expression after either serum stimulation or B-Raf:ER* activation (128). In
contrast to the induction of c-Myc mRNA by Raf, the induction of cyclin D1 mRNA was entirely abrogated by pretreatment of the cells with cycloheximide. These data are consistent with the CSF-1-mediated induction of cyclin D1 mRNA which occurs in mid-G1 and is
cycloheximide sensitive (67). Given the differences in the
kinetics and cycloheximide sensitivities of the c-Myc and cyclin D1
genes, it seems likely that Raf regulates these genes by different mechanisms.
In order to determine whether the induction of cyclin D1 by Raf was
mediated by transcriptional activation of the cyclin D1 promoter,
B-Raf:ER*-expressing cells were transiently transfected with a
reporter construct consisting of 984 bp of the mouse cyclin D1 promoter
linked to luciferase. Activation of B-Raf:ER* led to a 17-fold
induction of cyclin D1 promoter activity (Fig. 2B), a finding in
agreement with previous work indicating that in certain circumstances
the MAP kinase pathway plays an important role in the regulation of
cyclin D1 expression (56). Collectively, these data suggest
that the cyclin D1 gene is a delayed-early transcriptional target of
Raf activation in NIH 3T3 cells.
Induction of ODC gene expression by Raf.
The c-Myc
transcription factor has been implicated in the regulation of cell
proliferation, differentiation, and apoptosis (5). c-Myc
acts in concert with a heterodimerization partner Max to transactivate
transcription through cis-acting sequences known as E-boxes
(CACGTG) (11, 12, 51, 84). A number of cellular
genes have been identified as potential targets for transactivation by
c-Myc, including ODC, an enzyme that catalyzes the rate-limiting step
in polyamine biosynthesis which is essential for cell proliferation (7, 33, 38). If the induction of c-Myc by Raf is of
functional consequence, it would be predicted that a c-Myc target gene
such as ODC would be induced by Raf in an E-box-dependent manner. We therefore sought to determine whether Raf activation was sufficient to
induce the expression of ODC. Activation of either Raf-1:ER or
B-Raf:ER* in NIH 3T3 cells led to a 17- to 36-fold induction of ODC
mRNA expression (Fig. 3A and data not
shown). Compared to HB-EGF, which is induced with immediate-early
kinetics, the induction of ODC mRNA was delayed, reaching maximum
levels 4 to 12 h after Raf activation (Fig. 3A) (70).
These data are consistent with a temporal requirement for
intermediate events between Raf activation and ODC mRNA induction.
|
Luc) or a reporter in which the
E-boxes were mutated (CACGTG
CACCTG),
rendering the reporter unresponsive to c-Myc (ODCLucS-5A)
(80). Activation of B-Raf:ER* led to a 3.7-fold
induction of ODCLuc activity, whereas ODCLucS-5A was
activated 2.3-fold (Fig. 3B). This 37% decrease in the ability of Raf
to activate the ODCLucS-5A reporter, although modest, was highly
reproducible in five separate experiments. Moreover, the residual
transactivation of the ODCLucS-5A construct by Raf is consistent
with the prevailing model of ODC transcriptional regulation that
suggests that c-Myc works in concert with other regulated transcription
factors to control ODC expression (1, 52, 75, 80, 81, 129).
These data suggest that c-Myc binding sites are required for the full
induction of ODC gene transcription in response to Raf activation.
Further support for a role for the Ras/Raf pathway in the regulation of
c-Myc and ODC expression came from separate experiments with human cell
lines. HCT-116 is a tumorigenic colon carcinoma cell line expressing a
mutationally activated form of Ki-Ras (G13D) and elevated levels of
c-Myc. Hke-3 cells are a nontumorigenic derivative of HCT-116 derived
by homologous-recombination-mediated ablation of the activated Ki-Ras
gene that expresses decreased levels of c-Myc (108). In
these cells the wild-type ODCLuc reporter was transactivated 90-fold
more efficiently in HCT-116 cells than in HKe-3 cells (data not shown).
This is consistent with the work of others showing increased ODC gene
expression in Ha-Ras-transformed fibroblasts treated with basic
fibroblast growth factor (39, 41, 71) and suggest that
Ras-activated signaling pathways may play a role in the regulation of
c-Myc and ODC in the context of human cancer cells.
Complementation of defective CSF-1 receptor signaling by Raf. To further address the significance of c-Myc and cyclin D1 induction by Raf, we made use of two clonal NIH 3T3 cell lines expressing either the human CSF-1 receptor (CSF-1R) or a mutated derivative containing a tyrosine-to-phenylalanine mutation at a site of ligand-dependent phosphorylation (CSF-1R[809F]) (94, 97, 98). Addition of CSF-1 to NIH 3T3 cells expressing the human CSF-1 receptor leads to the induction of c-Fos, c-Jun, c-Myc, and cyclin D1 and elicits a robust proliferative response. Although the binding of CSF-1 to the mutated CSF-1 receptor elicits tyrosine phosphorylation of the receptor and induced expression of c-Jun and c-Fos, it fails to fully induce cyclin D1 and c-Myc mRNAs, with the consequence that the cells fail to proliferate in response to CSF-1 (98). The mitogenic defect of the CSF-1R[809F] is complemented by the ectopic overexpression of either cyclin D1 or c-Myc (95, 99). Since Raf activation resulted in the induction of both c-Myc and cyclin D1, we wished to examine whether the mutated CSF-1 receptor was able to activate the Raf/MEK/MAP kinase pathway and whether Raf could functionally complement the biochemical and biological defects in the CSF-1R[809F]-expressing cells.
To investigate the ability of the normal and mutated CSF-1 receptors to activate the Raf/MEK/MAP kinase pathway in NIH 3T3 cells, quiescent cells of both types were treated with CSF-1 for different periods of time from 5 to 60 min, and the MAP kinase activity was measured (Fig. 4A). Activation of the wild-type CSF-1 receptor led to activation of the p42 and p44 MAP kinases that peaked after 5 min of CSF-1 addition (~13-fold induction) and remained elevated (~5-fold induction) for up to 60 min after CSF-1 addition. By contrast, addition of CSF-1 to cells expressing the mutated CSF-1 receptor resulted in only a twofold activation of the MAP kinases over the same time period. These data indicate that despite the apparent inability of the CSF-1R[809F] to fully activate the MAP kinase pathway, this receptor retains its ability to induce the expression of c-Fos and c-Jun (98). Such data are consistent with a requirement for MAP kinase activation for induced expression of c-Myc and cyclin D1 mRNAs.
|
Raf-1:ER proteins that carry a
deletion of the CR1 and CR2 negative regulatory regions. This allows a
larger range of 4-HT concentrations in which the activation of Raf
alone is insufficient to induce cell proliferation (128). In
addition, since the presence of aspartic acid residues at these
positions is thought to mimic phosphorylation, this form of Raf-1 may
be a more accurate mimic of the protein that has been activated as a
consequence of growth factor receptor engagement. NIH 3T3 cells
expressing CSF-1R[809F] were infected with a retrovirus encoding
Raf-1[DD]:ER, and pooled populations of cells expressing
both proteins, referred to as
CSF-1R[809F]/Raf-1[DD]:ER, were established.
To determine if Raf activation was able to rescue the biochemical
defects in cells expressing CSF-1R[809F], cells were rendered quiescent and then stimulated with either CSF-1, 10% (vol/vol) FCS,
4-HT, or 4-HT plus CSF-1 for different lengths of time, and the
expression of c-Myc and cyclin D1 proteins was assessed by Western
blotting. CSF-1 treatment of cells expressing the wild-type CSF-1
receptor led to a strong induction of both cyclin D1 and c-Myc, whereas
CSF-1 treatment of CSF-1R[809F]-expressing cells resulted in poor
induction of both of these proteins even upon prolonged exposure of the
Western blot (Fig. 4C, left and middle panels) (99).
Activation of Raf-1[DD]:ER in the
CSF-1R[809F]/Raf-1[DD]:ER cells either alone or in
combination with CSF-1 treatment led to induction of both cyclin D1 and
c-Myc (Fig. 4C, right panels). The combination of 4-HT plus CSF-1 did
not appear to potentiate the kinetics of cyclin D1 or c-Myc induction
by Raf-1[DD]:ER. These data indicate that activation of
Raf-1[DD]:ER complemented the signaling defect of cells
expressing the defective CSF-1 receptor, leading to restoration of
induced c-Myc and cyclin D1 expression.
To determine if Raf-1[DD]:ER was able to complement the
mitogenic defect in CSF-1R[809F]-expressing cells, cells were
rendered quiescent and then treated with either CSF-1, 10% (vol/vol)
FCS, 4-HT, or CSF-1 plus 4-HT, and reentry into the cell cycle was
assessed by evaluating [methyl-3H]thymidine
incorporation into DNA. Treatment of CSF-1R-expressing cells with
either serum or CSF-1 led to induction of DNA synthesis, whereas 4-HT
had no effect (Fig. 4D, left panel). Cells expressing the defective
CSF-1 receptor responded to serum stimulation but not to either CSF-1
or 4-HT (Fig. 4D, left panel) (97). Quiescent CSF-1R[809F]/Raf-1[DD]:ER cells displayed a mitogenic response to serum stimulation but not to CSF-1 or activation of Raf-1[DD]:ER alone (Fig. 4D, right panel). However, concomitant activation of Raf-1[DD]:ER with CSF-1
treatment resulted in a synergistic mitogenic response that was not
observed with either 4-HT or CSF-1 treatment alone. Although activation of Raf is sufficient to induce mitogenesis in NIH 3T3 cells, these experiments were conducted at levels of Raf activation (modulated by
titrating the concentration of 4-HT) that were insufficient to induce
DNA synthesis (Fig. 4D, right panel, open bars).
Interestingly, in multiple experiments we noted that the response of
cells expressing the mutated CSF-1 receptor to concomitant treatment
with CSF-1 and Raf activation was less than that observed in cells
expressing the wild-type CSF-1 receptor. There are several possibilities to explain such observations. First, it may be that the
phosphorylation of tyrosine-809 of the CSF-1 receptor initiates multiple signaling pathways required for cell cycle progression. Second, it is possible that the mutated CSF-1 receptor is defective in
all Ras-activated signaling pathways; hence, Raf may only partially complement the loss of activated Ras. Third, such differences may be a
reflection of intrinsic clonal variation between separately derived
populations of NIH 3T3 cells. Finally, these results may be a
reflection of the ability of Raf to inhibit cell proliferation as a
consequence of the induction of p21Cip1 which could be
occurring in a subpopulation of retrovirus-infected cells
(128). Nonetheless, collectively, these data are consistent with a model that suggests that the defective CSF-1 receptor is unable
to fully activate the MAP kinase pathway leading to c-Myc and cyclin D1
induction. Moreover, activation of Raf in conjunction with CSF-1 is
sufficient to restore, at least in part, the biochemical and biological
response of these cells.
MEK activation is necessary and sufficient for the induction of
c-Myc and cyclin D1.
To determine whether MEK activation was
either necessary or sufficient for c-Myc and cyclin D1 induction, we
constructed a conditionally active form of MEK1 (MEK1:ER) by fusing
sequences encoding a constitutively active form of the protein to the
hormone-binding domain of the human estrogen receptor as described
previously (64, 128). In addition, we used a specific and
selective inhibitor of MEK1 (PD098059) to address whether MEK1 activity
was required for the induction of c-Myc and cyclin D1 by growth factors
and oncogenes.
MEK1:ER in NIH 3T3 cells led to activation of the p42
and p44 MAP kinases and elicited morphological transformation, although
both effects occurred with slower kinetics than was observed previously
with Raf-1:ER (Fig. 5B and 5C and data
not shown). In addition, activation of MEK1:ER in quiescent NIH 3T3
cells led to the induction of c-Myc and cyclin D1 that was detected between 3 and 26 h after the activation of MEK1:ER. The
expression of both proteins remained elevated for at least 48 h
after MEK1:ER activation (Fig. 5C). The delayed induction of both
proteins, compared to Raf activation, correlates with the slower
activation of the MAP kinases observed in response to MEK1:ER
activation (Fig. 5C, lower panel). However, c-Myc and cyclin D1 were
induced to the same extent by MEK1:ER as by Raf. These data indicate that MEK1 activation is sufficient for the induction of c-Myc and
cyclin D1 and are consistent with the ability of activated forms of
MEK1 to induce DNA synthesis in NIH 3T3 cells (19, 128).
|
B-Raf:ER* with PD098059, a specific and selective
inhibitor of MEK1 activity or dimethyl sulfoxide (DMSO) as a solvent
control (4, 128). Cells were then treated with increasing
concentrations of 4-HT and harvested after either 6 h (to measure
c-Myc expression) or 25 h (to measure cyclin D1 expression) (Fig.
5D). By 6 h after B-Raf:ER* activation, p42 and p44 MAP kinase
activation was readily detected with a phospho-specific anti-active MAP
kinase antiserum (Fig. 5D, top panel) or by an immune-complex kinase
assay (data not shown). Activation of the p42 and p44 MAP kinases was
inhibited by treatment with PD098059, whereas the addition of DMSO had
no effect. Treatment of cells with PD098059 inhibited the induction of
both c-Myc and cyclin D1 proteins in response to B-Raf:ER*
activation. However, at higher levels of Raf activation (25 nM 4-HT),
the inhibition of c-Myc and cyclin D1 expression by PD098059 was less
profound. It is not clear if this incomplete inhibition is a
consequence of only a partial blockade of MAP kinase activation in
these cells or if it may reflect that, at higher levels of Raf
activation, MEK-independent pathways are involved in the regulation of
these genes. However, these data suggest that MEK activity is required for the full induction of c-Myc and cyclin D1 in response to Raf activation.
To determine whether MEK activity is required for the ability of the
CSF-1 receptor to induce c-Myc expression, quiescent NIH 3T3 cells
expressing the wild-type CSF-1 receptor were treated with different
concentrations of CSF-1 (300 or 225 nM) in the absence or presence of
PD098059 (Fig. 5E). Cells were harvested after either 1 or 22.5 h
of CSF-1 treatment for analysis of c-Myc and cyclin D1 expression,
respectively. The induction of both c-Myc and cyclin D1 proteins by
CSF-1 was significantly inhibited in the presence of PD098059,
indicating that MEK activity is required for the full induction of
these proteins by CSF-1. These data are further consistent with a
requirement for MAP kinase activation for induction of c-Myc and cyclin
D1 by the CSF-1 receptor. As described above for Raf, it is not clear
if the residual expression of cyclin D1 and c-Myc is due to incomplete
inhibition of the MAP kinase pathway or the existence of
MEK1-independent pathways leading to the control of these genes.
Finally, we addressed the requirement for MEK activity in NIH 3T3 cells
for the induction of c-Myc in response to the potent mesenchymal growth
factor, platelet-derived growth factor (PDGF). Quiescent NIH 3T3 cells
were stimulated with PDGF in the absence or presence of PD098059. The
induction of c-Myc in response to PDGF was strongly inhibited by
PD098059 (Fig. 5F). Interestingly, treatment of these cells with
wortmannin, an inhibitor of PI3' kinase activity, also decreased
PDGF-induced c-Myc expression, suggesting a potential role for
phosphatidylinositol lipid-regulated signaling pathways in the
regulation of c-Myc expression (Fig. 5F).
Complementation of defective CSF-1 receptor signaling by v-Src. Previous experiments have indicated a potential role for the Src family of protein tyrosine kinases in the regulation of c-Myc expression in response to growth factor stimulation of mouse fibroblasts. Further, it has been suggested that a Src-dependent, Ras-independent pathway may be crucial in the regulation of c-Myc in such cells (6). We therefore sought to determine if activated Src could regulate either c-Myc or cyclin D1 expression and, additionally, if Src could complement the mitogenic defect in NIH 3T3 cells expressing the CSF-1R[809F]. A conditionally active form of v-Src was constructed by fusing sequences encoding the Schmidt Ruppin A form of v-Src to the hormone-binding domain of the human estrogen receptor as described above for Raf-1 and MEK1 (Fig. 6A). NIH 3T3 cells expressing v-Src:ER displayed hormone-dependent morphological transformation (Fig. 6B) and tyrosine phosphorylation of cellular proteins (Fig. 6C). As shown previously, treatment of NIH 3T3 cells infected with a control retrovirus (Neo) with 4-HT had no effect on the low level of tyrosine phosphorylation found in these cells and no effect on cell morphology (Fig. 6C) (100).
|
Raf-1:ER, suggesting
that v-Src:ER is able to activate some of the same changes in gene
expression induced by activation of Raf and MEK. Such results are
consistent with previous observations that transformation of cells by
v-Src requires the activity of Ras proteins (110).
|
| |
DISCUSSION |
|---|
|
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References
|
|---|
Considerable effort is currently focused on forging connections between components of the cytoplasmic signal transduction machinery, transcription factors, and regulators of the cell cycle. Although the precise details remain incompletely understood, the prevailing model suggests that engagement of growth factor receptors by their cognate ligands results in activation of numerous signaling pathways that modulate gene expression leading ultimately to an appropriate biological response. Since activated growth factor receptors influence a diverse array of cytosolic signal transduction pathways, attempts are under way to link specific signal transduction pathways with the activation of particular downstream target genes.
Several lines of evidence have suggested that in mouse fibroblasts Ras regulates the expression of the Fos and Jun components of the AP-1 transcription factor, whereas a Src-dependent, Ras-independent signaling pathway mediates c-Myc expression (6, 26). First, classical experiments on oncogene cooperation indicated that ectopically introduced Ras and Myc cooperate efficiently to transform primary murine cells and to accelerate tumor formation in mice (10, 90, 105, 133). Second, MAP kinase activation was implicated in the phosphorylation of the ternary complex factor Elk-1 which binds to the serum response element in the c-Fos promoter and contributes to the activation of c-Fos transcription (85). Third, activation of the human CSF-1 receptor in NIH 3T3 cells leads to the induction of c-Fos, c-Jun, c-Myc, and cyclin D1 expression and reentry into the cell cycle. Cells expressing a mutated form of the CSF-1 receptor induce c-Fos and c-Jun but do not induce c-Myc and cyclin D1 and fail to proliferate in response to CSF-1. The fact that the CSF-1R[809F] is capable of inducing the expression of c-Fos provided circumstantial evidence for the normal functioning of the Ras-activated MAP kinase pathway. The failure to induce c-Myc and cyclin D1 was taken as evidence that a separate pathway leading to the expression of these genes was compromised by mutation. Since this mutated receptor fails to associate with c-Src and can be complemented by the ectopic overexpression of c-Myc or cyclin D1, these results provided evidence for the possible existence of a Ras-independent pathway(s) leading to the expression of these proteins (18, 97-99). Finally, microinjection studies of PDGF-induced mitogenesis in NIH 3T3 cells suggested that the effects of dominant-negative Ras were overcome by ectopic overexpression of AP-1 but not of c-Myc, whereas the effects of dominant-negative c-Src were overcome by ectopic overexpression of c-Myc but not of AP-1. These data suggested that Ras functions upstream of c-Fos and c-Jun (AP-1), whereas c-Src and its family members function upstream of c-Myc. However, the inability to conduct biochemical analyses of microinjected cells precluded a more definitive analysis of the regulation of the c-Myc and AP-1 transcription factors in these latter experiments (6).
In these studies we demonstrate a link between the activation of the Raf/MEK/MAP kinase pathway and the transcriptional activation of c-Myc and cyclin D1. The kinetics of induction of these genes by Raf is fully consistent with previously published data on their induction by serum and growth factors: Raf activation leads to the immediate-early induction of c-Myc transcription and delayed induction of cyclin D1. Evidence that the induction of c-Myc by Raf was functionally productive was inferred from the ability of Raf to induce the expression of a known c-Myc-responsive gene, ODC, in a manner that is at least partly dependent on tandem E-boxes in the first intron of the gene (7). Interestingly, of five c-Myc responsive target genes that we tested, only ODC was significantly induced after Raf activation, suggesting that there are additional factors influencing the expression of c-Myc target genes. These may include the expression or activity of the transcription factor AP-2, which has been suggested to influence c-Myc-mediated transcriptional activation (31).
The work of other investigators also supports a connection between the Ras-activated MAP kinase pathway and the expression of c-Myc. The level of c-Myc mRNA is decreased after the ablation of activated Ki-Ras in human colon carcinoma cells. In addition, c-Myc expression is upregulated in Swiss 3T3 cells transformed by oncogenic Ha-Ras (59, 108). Furthermore, it has been suggested that Raf is involved in the induction of c-Myc transcription in response to v-abl activation and growth factor stimulation (48, 137). It has also been demonstrated that Ras transformation of NIH 3T3 cells is inhibited by the expression of dominant-negative forms of c-Myc or by the inhibition of c-Myc expression (109). Finally, it is likely that regulation of c-Myc by the MAP kinase pathway is not limited to transcriptional control of c-Myc gene expression. It has been reported that MAP kinase-mediated phosphorylation of c-Myc modulates its transforming and transactivation potential and that MAP kinase and c-Myc physically associate with each other (17, 34, 88, 106). It will be important to fully characterize the transcriptional and posttranslational interactions between the MAP kinase pathway and c-Myc in order to properly understand their functional relationship. It should further be emphasized that the ability of the MAP kinase pathway to induce the expression of c-Myc and cyclin D1 in NIH 3T3 cells does not preclude an important role for other growth factor-activated signaling pathways in the expression of these proteins in fibroblasts or indeed in other cell types (102, 116).
Our studies of NIH 3T3 cells expressing the CSF-1R and CSF-1R[809F] provide additional evidence for a functional connection between the Raf/MEK/MAP kinase pathway and cyclin D1 and c-Myc. NIH 3T3 cells expressing CSF-1R[809F] are defective in their ability to activate the p42 and p44 MAP kinases in response to CSF-1 stimulation, a finding consistent with a model that places the MAP kinase pathway upstream of c-Myc and cyclin D1. Importantly, in cells expressing CSF-1R[809F], activation of the MAP kinase pathway mediated either by activated Raf-1 or v-Src complemented, at least in part, both the biochemical and the biological defects in these cells. Further evidence for a role for the MAP kinase pathway in growth factor- and oncogene-induced c-Myc and cyclin D1 expression was demonstrated by the use of a specific and selective MEK inhibitor, PD098059, which prevented the induction of c-Myc and cyclin D1 in response to both growth factors and oncogenes. Despite the strong connection between the MAP kinase pathway and the expression of c-Myc and cyclin D1 observed in these experiments, we cannot rule out the possibility that there are additional signaling pathways activated as a consequence of the phosphorylation of tyrosine-809 of the human CSF-1 receptor that participate in the regulation of these genes.
A possible resolution for some of the apparent discrepancies in the literature may reflect the mechanism of Raf-1 activation in response to growth factor stimulation. The current model suggests that activated Ras recruits Raf-1 to the plasma membrane, where it is phosphorylated by members of the Src family of protein tyrosine kinases. Phosphorylation of Raf-1 on these sites (Y340 and Y341) significantly potentiates its ability to activate the MAP kinase pathway. Indeed, the form of the conditionally active full-length Raf-1 that we used in these experiments is thought to be at least a partial mimic of the tyrosine phosphorylated form of the protein (14, 27, 65, 66). Therefore, inhibitors of both Ras and Src might be expected to interfere with the normal activation of the Raf/MEK/MAP kinase pathway and the subsequent induction of c-Myc and cyclin D1. Such a model is consistent with the observations that the activation of the wild-type CSF-1 receptor results in activation of c-Src but that the CSF-1R[809F] fails to associate with c-Src (18).
An important role for the Ras-activated MAP kinase pathway in the transmission of mitogenic signals from Src is supported by the work of others. For example, transformation by v-Src is inhibited by neutralizing anti-Ras antibodies or by overexpression of GAP (21, 79, 110). Furthermore, the Ras-activated MAP kinase pathway has been shown to be required for induction of certain Src transcriptional target genes (20, 89, 131). Finally, the phenotypic effects of overexpression of a Drosophila homologue of a Src-family kinase are inhibited by loss of Ras function (115).
Although we have not defined the cis-acting elements in either the c-Myc or cyclin D1 promoters that confer Raf responsiveness, there may be a role for Ets-family transcription factors in the transcriptional regulation of these genes. The importance of Ets transcription factors in mediating both growth factor- and oncogene-induced gene expression is illustrated by the fact that both Ets-1 and Ets-2 rescue the mitogenic defect in CSF-1R[809F]-expressing cells (96). In addition, dominant-negative forms of Ets-2 have been shown to suppress induction of c-Myc and cyclin D1 by CSF-1 and epidermal growth factor (EGF), respectively (2, 55). Dominant-negative Ets-2 has also been shown to suppress morphological transformation induced by v-Raf and CSF-1 (55, 101). Further, induction of the cyclin D1 promoter has been shown to be suppressed by the ectopic expression of dominant-negative MEK1 or MAP kinase phosphatase 1 (56). These results are consistent with the inability of the mutated CSF-1 receptor to activate the MAP kinase-mediated phosphorylation of Ets-2 in NIH 3T3 cells (28, 69, 134).
Since the CSF-1R[809F] is unable to fully activate the MAP kinase pathway and yet induces the expression of c-Fos, these data call into question the role of the MAP kinase pathway in c-Fos expression (119). In separate experiments, we have assessed the effects of Raf activation on the expression of c-Fos. Unlike c-Myc and cyclin D1, Raf activation does not mimic the effects of growth factor stimulation on c-Fos mRNA or protein expression inducing, at best, only a modest increase in c-Fos expression (17a). However, when Raf activation is combined with a second signal such as a calcium agonist, a strong synergistic induction of c-Fos expression is observed. A requirement for the MAP kinase pathway in the regulation of c-Fos was inferred from the fact that treatment of cells with PD098059 prevented c-Fos induction by serum or EGF. These data suggest that the MAP kinase pathway is required for c-Fos induction in response to mitogens but that maximal induction of c-Fos may require the cooperation of other signaling pathways. Such conclusions are supported by studies utilizing transgenic mice containing c-Fos reporter constructs, as well as by recent studies of the effects of Rho-family GTPases on c-Fos expression that indicate that c-Fos regulation is significantly more complex than earlier studies had indicated (3, 91). Clearly, future experiments must be dedicated to gaining a more precise understanding of the biochemical mechanisms underlying these transcriptional responses and the ultimate phenotypic consequences of such changes on cell physiology.
| |
ACKNOWLEDGMENTS |
|---|
We gratefully acknowledge the members of the McMahon and Lees laboratories for helpful discussions. In addition we thank Bob Eisenman and Martine Roussel for critical review of the manuscript. We thank Natalie Ahn, Naoko Arai, J. Michael Bishop, Steve Clark, John Cleveland, Simon Cook, Philip Coffino, Bob Eisenman, Gerard Evan, Nissim Hay, Josh Kaplan, John Lyons, Jay Morgenstern, Debbie Morrison, Mike Ostrowski, David Parry, Gordon Peters, Martine Roussel, Chuck Toth, and Alan Wakeling for generously providing reagents, for helpful discussions, and for communicating unpublished observations.
DNAX Research Institute is supported by the Schering Plough Corporation.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Cancer Research Institute, UCSF/Mt. Zion Cancer Center, 2340 Sutter St., San Francisco, CA 94115. Phone: (415) 502-5829. Fax: (415) 502-3179. E-mail: mcmahon{at}cc.ucsf.edu.
| |
REFERENCES |
|---|
|
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References
|
|---|
| 1. |
Abrahamsen, M. S.,
R. S. Li,
W. Dietrich-Goetz, and D. R. Morris.
1992.
Multiple DNA elements responsible for transcriptional regulation of the ornithine decarboxylase gene by protein kinase A.
J. Biol. Chem.
267:18866-18873 |
| 2. |
Albanese, C.,
J. Johnson,
G. Watanabe,
N. Eklund,
D. Vu,
A. Arnold, and R. G. Pestell.
1995.
Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions.
J. Biol. Chem.
270:23589-23597 |
| 3. | Alberts, A. S., O. Geneste, and R. Treisman. 1998. Activation of SRF-regulated chromosomal templates by Rho-family GTPases requires a signal that also induces H4 hyperacetylation. Cell 92:475-487[Medline]. |
| 4. |
Alessi, D. R.,
A. Cuenda,
P. Cohen,
D. T. Dudley, and A. R. Saltiel.
1995.
PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo.
J. Biol. Chem.
270:27489-27494 |
| 5. | Amati, B., and H. Land. 1994. Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation and death. Curr. Opin. Genet. Dev. 4:102-108[Medline]. |
| 6. | Barone, M. V., and S. A. Courtneidge. 1995. Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src. Nature 378:509-512[Medline]. |
| 7. |
Bello-Fernandez, C.,
G. Packham, and J. L. Cleveland.
1993.
The ornithine decarboxylase gene is a transcriptional target of c-Myc.
Proc. Natl. Acad. Sci. USA
90:7804-7808 |
| 8. | Bennett, M. R., S. Anglin, J. R. McEwan, R. Jagoe, A. C. Newby, and G. I. Evan. 1994. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J. Clin. Investig. 93:820-828. |
| 9. |
Bennett, M. R.,
G. I. Evan, and A. C. Newby.
1994.
Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of rat vascular smooth muscle cells by serum reduction, interferon-gamma, heparin, and cyclic nucleotide analogues and induces apoptosis.
Circ. Res.
74:525-536 |
| 10. |
Birrer, M. J.,
S. Segal,
J. S. De Greve,
F. Kaye,
E. A. Sausville, and J. D. Minna.
1988.
L-myc cooperates with ras to transform primary rat embryo fibroblasts.
Mol. Cell. Biol.
8:2668-2673 |
| 11. |
Blackwell, T. K.,
L. Kretzner,
E. M. Blackwood,
R. N. Eisenman, and H. Weintraub.
1990.
Sequence-specific DNA binding by the c-Myc protein.
Science
250:1149-1151 |
| 12. |
Blackwood, E. M., and R. N. Eisenman.
1991.
Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc.
Science
251:1211-1217 |
| 13. |
Bos, J. L.
1989.
ras oncogenes in human cancer: a review.
Cancer Res.
49:4682-4689 |
| 14. | Bosch, E., H. Cherwinski, D. Peterson, and M. McMahon. 1997. Mutations of critical amino acids affect the biological and biochemical properties of oncogenic A-Raf and Raf-1. Oncogene 15:1021-1033[Medline]. |
| 15. |
Brabant, M.,
L. McConlogue,
T. van Daalen Wetters, and P. Coffino.
1988.
Mouse ornithine decarboxylase gene: cloning, structure, and expression.
Proc. Natl. Acad. Sci. USA
85:2200-2204 |
| 16. | Collins, J. F., P. Herman, C. Schuch, and G. C. Bagby, Jr. 1992. c-myc antisense oligonucleotides inhibit the colony-forming capacity of Colo 320 colonic carcinoma cells. J. Clin. Investig. 89:1523-1527. |
| 17. |
Colman, M. S., and M. C. Ostrowski.
1996.
The transactivation potential of a c-Myc N-terminal region (residues 92-143) is regulated by growth factor/Ras signaling.
Nucleic Acids Res.
24:1971-1978 |
| 17a. |
Cook, S. J.,
N. Aziz, and M. McMahon.
1999.
The repertoire of Fos and Jun proteins expressed during the G1 phase of the cell cycle is determined by the duration of mitogen-activated protein kinase activation.
Mol. Cell. Biol.
19:330-341 |
| 18. | Courtneidge, S. A., R. Dhand, D. Pilat, G. M. Twamley, M. D. Waterfield, and M. F. Roussel. 1993. Activation of Src family kinases by colony stimulating factor-1, and their association with its receptor. EMBO J. 12:943-950[Medline]. |
| 19. | Cowley, S., H. Paterson, P. Kemp, and C. J. Marshall. 1994. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77:841-852[Medline]. |
| 20. |
D'Arcangelo, G., and S. Halegoua.
1993.
A branched signaling pathway for nerve growth factor is revealed by Src-, Ras-, and Raf-mediated gene inductions.
Mol. Cell. Biol.
13:3146-3155 |
| 21. |
DeClue, J. E.,
K. Zhang,
P. Redford,
W. C. Vass, and D. R. Lowy.
1991.
Suppression of src transformation by overexpression of full-length GTPase-activating protein (GAP) or of the GAP C terminus.
Mol. Cell. Biol.
11:2819-2825 |
| 22. |
Dent, P.,
W. Haser,
T. A. Haystead,
L. A. Vincent,
T. M. Roberts, and T. W. Sturgill.
1992.
Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro.
Science
257:1404-1407 |
| 23. | Dickson, B., F. Sprenger, D. Morrison, and E. Hafen. 1992. Raf functions downstream of Ras1 in the Sevenless signal transduction pathway. Nature 360:600-603[Medline]. |
| 24. | Downward, J. 1997. Cell cycle: routine role for Ras. Curr. Biol. 7:R258-R260[Medline]. |
| 25. | Downward, J. 1992. Regulation of p21ras by GTPase activating proteins and guanine nucleotide exchange proteins. Curr. Opin. Genet. Dev. 2:13-18[Medline]. |
| 26. | Eisenman, R. N., and J. A. Cooper. 1995. Signal transduction. Beating a path to Myc. Nature 378:438-439[Medline]. |
| 27. |
Fabian, J. R.,
I. O. Daar, and D. K. Morrison.
1993.
Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase.
Mol. Cell. Biol.
13:7170-7179 |
| 28. |
Fowles, L. F.,
M. L. Martin,
L. Nelsen,
K. J. Stacey,
D. Redd,
Y. M. Clark,
Y. Nagamine,
M. McMahon,
D. A. Hume, and M. C. Ostrowski.
1998.
Persistent activation of mitogen-activated protein kinases p42 and p44 and ets-2 phosphorylation in response to colony-stimulating factor 1/c-fms signaling.
Mol. Cell. Biol.
18:5148-5156 |
| 29. | Fumagalli, S., N. F. Totty, J. J. Hsuan, and S. A. Courtneidge. 1994. A target for Src in mitosis. Nature 368:871-874[Medline]. |
| 30. | Garte, S. J. 1993. The c-myc oncogene in tumor progression. Crit. Rev. Oncog. 4:435-449[Medline]. |
| 31. | Gaubatz, S., A. Imhof, R. Dosch, O. Werner, P. Mitchell, R. Buettner, and M. Eilers. 1995. Transcriptional activation by Myc is under negative control by the transcription factor AP-2. EMBO J. 14:1508-1519[Medline]. |
| 32. | Gomez, N., and P. Cohen. 1991. Dissection of the protein kinase cascade by which nerve growth factor activates MAP kinase. Nature 353:170-173[Medline]. |
| 33. | Grandori, C., and R. N. Eisenman. 1997. Myc target genes. Trends Biochem. Sci. 22:177-181[Medline]. |
| 34. | Gupta, S., and R. J. Davis. 1994. MAP kinase binds to the NH2-terminal activation domain of c-Myc. FEBS Lett. 353:281-285[Medline]. |
| 35. | Hall, M., and G. Peters. 1996. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res. 68:67-108[Medline]. |
| 36. | Han, M., A. Golden, Y. Han, and P. W. Sternberg. 1993. C. elegans lin-45 raf gene participates in let-60 ras-stimulated vulval differentiation. Nature 363:133-140[Medline]. |
| 37. |
Hann, S. R., and R. N. Eisenman.
1984.
Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells.
Mol. Cell. Biol.
4:2486-2497 |
| 38. | Heby, O., and L. Persson. 1990. Molecular genetics of polyamine synthesis in eukaryotic cells. Trends Biochem. Sci. 15:153-158[Medline]. |
| 39. |
Holtta, E.,
L. Sistonen, and K. Alitalo.
1988.
The mechanisms of ornithine decarboxylase deregulation in c-Ha-ras oncogene-transformed NIH 3T3 cells.
J. Biol. Chem.
263:4500-4507 |
| 40. |
Howe, L. R., and C. J. Marshall.
1993.
Lysophosphatidic acid stimulates mitogen-activated protein kinase activation via a G-protein-coupled pathway requiring p21ras and p74raf-1.
J. Biol. Chem.
268:20717-20720 |
| 41. | Hurta, R. A., A. Huang, and J. A. Wright. 1996. Basic fibroblast growth factor selectively regulates ornithine decarboxylase gene expression in malignant H-ras transformed cells. J. Cell. Biochem. 60:572-583[Medline]. |
| 42. |
Johnson, L.,
D. Greenbaum,
K. Cichowski,
K. Mercer,
E. Murphy,
E. Schmitt,
R. T. Bronson,
H. Umanoff,
W. Edelmann,
R. Kucherlapati, and T. Jacks.
1997.
K-ras is an essential gene in the mouse with partial functional overlap with N-ras.
Genes Dev.
11:2468-2481 |
| 43. | Johnston, J. M., and W. L. Carroll. 1992. c-myc hypermutation in Burkitt's lymphoma. Leuk. Lymphoma 8:431-439[Medline]. |
| 44. | Joneson, T., and D. Bar-Sagi. 1997. Ras effectors and their role in mitogenesis and oncogenesis. J. Mol. Med. 75:587-593[Medline]. |
| 45. |
Kaplan, J. M.,
G. Mardon,
J. M. Bishop, and H. E. Varmus.
1988.
The first seven amino acids encoded by the v-src oncogene act as a myristylation signal: lysine 7 is a critical determinant.
Mol. Cell. Biol.
8:2435-2441 |
| 46. | Katz, M. E., and F. McCormick. 1997. Signal transduction from multiple Ras effectors. Curr. Opin. Genet. Dev. 7:75-79[Medline]. |
| 47. | Kelly, K., B. H. Cochran, C. D. Stiles, and P. Leder. 1983. Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell 35:603-610[Medline]. |
| 48. | Kerkhoff, E., R. Houben, S. Loffler, J. Troppmair, J. E. Lee, and U. R. Rapp. 1998. Regulation of c-myc expression by Ras/Raf signalling. Oncogene 16:211-6[Medline]. |
| 49. | Khosravi-Far, R., and C. J. Der. 1994. The Ras signal transduction pathway. Cancer Metastasis Rev. 13:67-89[Medline]. |
| 50. | Kolch, W., G. Heidecker, P. Lloyd, and U. R. Rapp. 1991. Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature 349:426-428[Medline]. |
| 51. | Kretzner, L., E. M. Blackwood, and R. N. Eisenman. 1992. Myc and Max proteins possess distinct transcriptional activities. Nature 359:426-429[Medline]. |
| 52. |
Kumar, A. P.,
P. K. Mar,
B. Zhao,
R. L. Montgomery,
D. C. Kang, and A. P. Butler.
1995.
Regulation of rat ornithine decarboxylase promoter activity by binding of transcription factor Sp1.
J. Biol. Chem.
270:4341-4348 |
| 53. | Kyriakis, J. M., H. App, X. F. Zhang, P. Banerjee, D. L. Brautigan, U. R. Rapp, and J. Avruch. 1992. Raf-1 activates MAP kinase-kinase. Nature 358:417-421[Medline]. |
| 54. |
Lahti, J. M.,
H. Li, and V. J. Kidd.
1997.
Elimination of cyclin D1 in vertebrate cells leads to an altered cell cycle phenotype, which is rescued by overexpression of murine cyclins D1, D2, or D3 but not by a mutant cyclin D1.
J. Biol. Chem.
272:10859-10869 |
| 55. |
Langer, S. J.,
D. M. Bortner,
M. F. Roussel,
C. J. Sherr, and M. C. Ostrowski.
1992.
Mitogenic signaling by colony-stimulating factor 1 and ras is suppressed by the ets-2 DNA-binding domain and restored by myc overexpression.
Mol. Cell. Biol.
12:5355-5362 |
| 56. |
Lavoie, J. N.,
G. L'Allemain,
A. Brunet,
R. Muller, and J. Pouyssegur.
1996.
Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway.
J. Biol. Chem.
271:20608-20616 |
| 57. |
Leonetti, C.,
I. D'Agnano,
F. Lozupone,
A. Valentini,
T. Geiser,
G. Zon,
B. Calabretta,
G. C. Citro, and G. Zupi.
1996.
Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice.
J. Natl. Cancer Inst.
88:419-429 |
| 58. | Li, M., H. Lonial, R. Citarella, D. Lindh, L. Colina, and R. Kramer. 1996. Tumor inhibitory activity of anti-ras ribozymes delivered by retroviral gene transfer. Cancer Gene Ther. 3:221-229[Medline]. |
| 59. | Lloyd, A. C., H. F. Paterson, J. D. Morris, A. Hall, and C. J. Marshall. 1989. p21H-ras-induced morphological transformation and increases in c-myc expression are independent of functional protein kinase C. EMBO J. 8:1099-1104[Medline]. |
| 60. |
Lu, X.,
T. B. Chou,
N. G. Williams,
T. Roberts, and N. Perrimon.
1993.
Control of cell fate determination by p21ras/Ras1, an essential component of torso signaling in Drosophila.
Genes Dev.
7:621-632 |
| 61. |
Luttrell, D. K.,
L. M. Luttrell, and S. J. Parsons.
1988.
Augmented mitogenic responsiveness to epidermal growth factor in murine fibroblasts that overexpress pp60c-src.
Mol. Cell. Biol.
8:497-501 |
| 62. | MacNicol, A. M., A. J. Muslin, and L. T. Williams. 1993. Raf-1 kinase is essential for early Xenopus development and mediates the induction of mesoderm by FGF. Cell 73:571-583[Medline]. |
| 63. | Mangues, R., I. Seidman, A. Pellicer, and J. W. Gordon. 1990. Tumorigenesis and male sterility in transgenic mice expressing a MMTV/N-ras oncogene. Oncogene 5:1491-1497[Medline]. |
| 64. |
Mansour, S. J.,
W. T. Matten,
A. S. Hermann,
J. M. Candia,
S. Rong,
K. Fukasawa,
G. F. Vande-Woude, and N. G. Ahn.
1994.
Transformation of mammalian cells by constitutively active MAP kinase.
Science
265:966-970 |
| 65. | Marais, R., Y. Light, H. F. Paterson, and C. J. Marshall. 1995. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J. 14:3136-3145[Medline]. |
| 66. |
Marais, R.,
Y. Light,
H. F. Paterson,
C. S. Mason, and C. J. Marshall.
1997.
Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases.
J. Biol. Chem.
272:4378-4383 |
| 67. | Matsushime, H., M. F. Roussel, R. A. Ashmun, and C. J. Sherr. 1991. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 65:701-713[Medline]. |
| 68. | McCarthy, S. A., N. Aziz, and M. McMahon. 1997. Identification of immediate-early gene targets of the Raf-1 serine/threonine protein kinase using an estradiol-dependent fusion protein, delta Raf-1:ER. Methods Mol. Biol. 85:137-151[Medline]. |
| 69. | McCarthy, S. A., D. Chen, B. S. Yang, J. J. Garcia Ramirez, H. Cherwinski, X. R. Chen, M. Klagsbrun, C. A. Hauser, M. C. Ostrowski, and M. McMahon. 1997. Rapid phosphorylation of Ets-2 accompanies mitogen-activated protein kinase activation and the induction of heparin-binding epidermal growth factor gene expression by oncogenic Raf-1. Mol. Cell. Biol. 17:2401-2412[Abstract]. |
| 70. |
McCarthy, S. A.,
M. L. Samuels,
C. A. Pritchard,
J. A. Abraham, and M. McMahon.
1995.
Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes.
Genes Dev.
9:1953-1964 |
| 71. | Mimori, K., M. Mori, T. Shiraishi, T. Fujie, K. Baba, H. Kusumoto, M. Haraguchi, H. Ueo, and T. Akiyoshi. 1997. Analysis of ornithine decarboxylase messenger ribonucleic acid expression in colorectal carcinoma. Dis. Colon Rectum 40:1095-1100[Medline]. |
| 72. |
Morgenstern, J. P., and H. Land.
1990.
Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line.
Nucleic Acids Res.
18:3587-3596 |
| 73. | Moriguchi, T., Y. Gotoh, and E. Nishida. 1996. Roles of the MAP kinase cascade in vertebrates. Adv. Pharmacol. 36:121-137. |
| 74. | Morrison, D. K., and R. E. Cutler. 1997. The complexity of Raf-1 regulation. Curr. Opin. Cell Biol. 9:174-179[Medline]. |
| 75. |
Moshier, J. A.,
D. L. Osborne,
M. Skunca,
J. Dosescu,
J. D. Gilbert,
M. C. Fitzgerald,
G. Polidori,
R. L. Wagner,
S. J. Friezner Degen,
G. D. Luk, et al.
1992.
Multiple promoter elements govern expression of the human ornithine decarboxylase gene in colon carcinoma cells.
Nucleic Acids Res.
20:2581-2590 |
| 76. | Nass, S. J., and R. B. Dickson. 1997. Defining a role for c-Myc in breast tumorigenesis. Breast Cancer Res. Treat. 44:1-22[Medline]. |
| 77. | Nishida, E., and Y. Gotoh. 1993. The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biochem. Sci. 18:128-131[Medline]. |
| 78. | Nishida, Y., Y. H. Inoue, L. Tsuda, T. Adachi-Yamada, Y. M. Lim, M. Hata, H. Y. Ha, and S. Sugiyama. 1996. The Raf/MAP kinase cascade in cell cycle regulation and differentiation in Drosophila. Cell Struct. Funct. 21:437-444[Medline]. |
| 79. |
Nori, M.,
U. S. Vogel,
J. B. Gibbs, and M. J. Weber.
1991.
Inhibition of v-src-induced transformation by a GTPase-activating protein.
Mol. Cell. Biol.
11:2812-2818 |
| 80. | Packham, G., and J. L. Cleveland. 1997. Induction of ornithine decarboxylase by IL-3 is mediated by sequential c-Myc-independent and c-Myc-dependent pathways. Oncogene 15:1219-1232[Medline]. |
| 81. | Palvimo, J. J., M. Partanen, and O. A. Janne. 1996. Characterization of cell-specific modulatory element in the murine ornithine decarboxylase promoter. Biochem. J. 316:993-998. |
| 82. | Parsons, J. T., and S. J. Parsons. 1997. Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways. Curr. Opin. Cell Biol. 9:187-192[Medline]. |
| 83. |
Pear, W. S.,
G. P. Nolan,
M. L. Scott, and D. Baltimore.
1993.
Production of high-titer helper-free retroviruses by transient transfection.
Proc. Natl. Acad. Sci. USA
90:8392-8396 |
| 84. |
Prendergast, G. C., and E. B. Ziff.
1991.
Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region.
Science
251:186-189 |
| 85. | Price, M. A., C. Hill, and R. Treisman. 1996. Integration of growth factor signals at the c-fos serum response element. Philos. Trans. R. Soc. Lond. B Biol. Sci. 351:551-559[Medline]. |
| 86. | Prins, J., E. G. De Vries, and N. H. Mulder. 1993. The myc family of oncogenes and their presence and importance in small-cell lung carcinoma and other tumour types. Anticancer Res. 13:1373-1385[Medline]. |
| 87. | Pritchard, C. A., M. L. Samuels, E. Bosch, and M. McMahon. 1995. Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells. Mol. Cell. Biol. 15:6430-6442[Abstract]. |
| 88. | Pulverer, B. J., C. Fisher, K. Vousden, T. Littlewood, G. Evan, and J. R. Woodgett. 1994. Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene 9:59-70[Medline]. |
| 89. |
Qureshi, S. A.,
M. Rim,
J. Bruder,
W. Kolch,
U. Rapp,
V. P. Sukhatme, and D. A. Foster.
1991.
An inhibitory mutant of c-Raf-1 blocks v-Src-induced activation of the Egr-1 promoter.
J. Biol. Chem.
266:20594-20597 |
| 90. | Rapp, U. R., J. L. Cleveland, S. M. Storm, T. W. Beck, and M. Huleihel. 1986. Transformation by raf and myc oncogenes. Princess Takamatsu Symp. 17:55-74[Medline]. |
| 91. | Robertson, L. M., T. K. Kerppola, M. Vendrell, D. Luk, R. J. Smeyne, C. Bocchiaro, J. I. Morgan, and T. Curran. 1995. Regulation of c-fos expression in transgenic mice requires multiple interdependent transcription control elements. Neuron 14:241-252[Medline]. |
| 92. | Robinson, M. J., and M. H. Cobb. 1997. Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 9:180-186[Medline]. |
| 93. |
Roche, S.,
S. Fumagalli, and S. A. Courtneidge.
1995.
Requirement for Src family protein tyrosine kinases in G2 for fibroblast cell division.
Science
269:1567-1569 |
| 94. | Roussel, M. F. 1997. Regulation of cell cycle entry and G1 progression by CSF-1. Mol. Reprod. Dev. 46:11-18[Medline]. |
| 95. | Roussel, M. F., J. L. Cleveland, S. A. Shurtleff, and C. J. Sherr. 1991. Myc rescue of a mutant CSF-1 receptor impaired in mitogenic signalling. Nature 353:361-363[Medline]. |
| 96. | Roussel, M. F., J. N. Davis, J. L. Cleveland, J. Ghysdael, and S. W. Hiebert. 1994. Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1. Oncogene 9:405-415[Medline]. |
| 97. |
Roussel, M. F., and C. J. Sherr.
1989.
Mouse NIH 3T3 cells expressing human colony-stimulating factor 1 (CSF-1) receptors overgrow in serum-free medium containing human CSF-1 as their only growth factor.
Proc. Natl. Acad. Sci. USA
86:7924-7927 |
| 98. |
Roussel, M. F.,
S. A. Shurtleff,
J. R. Downing, and C. J. Sherr.
1990.
A point mutation at tyrosine-809 in the human colony-stimulating factor 1 receptor impairs mitogenesis without abrogating tyrosine kinase activity, association with phosphatidylinositol 3-kinase, or induction of c-fos and junB genes.
Proc. Natl. Acad. Sci. USA
87:6738-6742 |
| 99. |
Roussel, M. F.,
A. M. Theodoras,
M. Pagano, and C. J. Sherr.
1995.
Rescue of defective mitogenic signaling by D-type cyclins.
Proc. Natl. Acad. Sci. USA
92:6837-6841 |
| 100. |
Samuels, M. L.,
M. J. Weber,
J. M. Bishop, and M. McMahon.
1993.
Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol-dependent human raf-1 protein kinase.
Mol. Cell. Biol.
13:6241-6252 |
| 101. |
Sapi, E.,
M. B. Flick,
S. Rodov, and B. M. Kacinski.
1998.
Ets-2 transdominant mutant abolishes anchorage-independent growth and macrophage colony-stimulating factor-stimulated invasion by BT20 breast carcinoma cells.
Cancer Res.
58:1027-1033 |
| 102. | Sato, N., K. Sakamaki, N. Terada, K. Arai, and A. Miyajima. 1993. Signal transduction by the high-affinity GM-CSF receptor: two distinct cytoplasmic regions of the common beta subunit responsible for different signaling. EMBO J. 12:4181-4189[Medline]. |
| 103. |
Schaap, D.,
J. van der Wal,
L. R. Howe,
C. J. Marshall, and W. J. van Blitterswijk.
1993.
A dominant-negative mutant of raf blocks mitogen-activated protein kinase activation by growth factors and oncogenic p21ras.
J. Biol. Chem.
268:20232-20236 |
| 104. | Schwab, M. 1994. Human neuroblastoma: amplification of the N-myc oncogene and loss of a putative cancer-preventing gene on chromosome 1p. Recent Results Cancer Res. 135:7-16[Medline]. |
| 105. |
Schwartz, R. C.,
L. W. Stanton,
S. C. Riley,
K. B. Marcu, and O. N. Witte.
1986.
Synergism of v-myc and v-Ha-ras in the in vitro neoplastic progression of murine lymphoid cells.
Mol. Cell. Biol.
6:3221-3231 |
| 106. |
Seth, A.,
E. Alvarez,
S. Gupta, and R. J. Davis.
1991.
A phosphorylation site located in the NH2-terminal domain of c-Myc increases transactivation of gene expression.
J. Biol. Chem.
266:23521-23524 |
| 107. | Sherr, C. J. 1995. Mammalian G1 cyclins and cell cycle progression. Proc. Assoc. Am. Physicians 107:181-186[Medline]. |
| 108. |
Shirasawa, S.,
M. Furuse,
N. Yokoyama, and T. Sasazuki.
1993.
Altered growth of human colon cancer cell lines disrupted at activated Ki-ras.
Science
260:85-88 |
| 109. |
Sklar, M. D.,
E. Thompson,
M. J. Welsh,
M. Liebert,
J. Harney,
H. B. Grossman,
M. Smith, and E. V. Prochownik.
1991.
Depletion of c-myc with specific antisense sequences reverses the transformed phenotype in ras oncogene-transformed NIH 3T3 cells.
Mol. Cell. Biol.
11:3699-3710 |
| 110. | Smith, M. R., S. J. DeGudicibus, and D. W. Stacey. 1986. Requirement for c-ras proteins during viral oncogene transformation. Nature 320:540-543[Medline]. |
| 111. | Snow, E. C. 1997. The role of c-myc during normal B-cell proliferation, and as B cells undergo malignant transformation. Curr. Top. Microbiol. Immunol. 224:211-220[Medline]. |
| 112. | Sternberg, P. W., and H. R. Horvitz. 1991. Signal transduction during C. elegans vulval induction. Trends Genet. 7:366-371[Medline]. |
| 113. | Stokoe, D., and F. McCormick. 1997. Activation of c-Raf-1 by Ras and Src through different mechanisms: activation in vivo and in vitro. EMBO J. 16:2384-2396[Medline]. |
| 114. | Storm, S. M., U. Brennscheidt, G. Sithanandam, and U. R. Rapp. 1990. raf oncogenes in carcinogenesis. Crit. Rev. Oncog. 2:1-8[Medline]. |
| 115. |
Takahashi, F.,
S. Endo,
T. Kojima, and K. Saigo.
1996.
Regulation of cell-cell contacts in developing Drosophila eyes by Dsrc41, a new, close relative of vertebrate c-src.
Genes Dev.
10:1645-1656 |
| 116. |
Terada, K.,
Y. Kaziro, and T. Satoh.
1995.
Ras is not required for the interleukin 3-induced proliferation of a mouse pro-B cell line, BaF3.
J. Biol. Chem.
270:27880-27886 |
| 117. | Thomas, S. M., and J. S. Brugge. 1997. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 13:513-609[Medline]. |
| 118. | Treisman, R. 1996. Regulation of transcription by MAP kinase cascades. Curr. Opin. Cell Biol. 8:205-215[Medline]. |
| 119. | Treisman, R. 1994. Ternary complex factors: growth factor regulated transcriptional activators. Curr. Opin. Genet. Dev. 4:96-101[Medline]. |
| 120. | Troppmair, J., and U. R. Rapp. 1997. Apoptosis regulation by Raf, Bcl-2, and R-Ras. Recent Results Cancer Res. 143:245-249[Medline]. |
| 121. |
Twamley-Stein, G. M.,
R. Pepperkok,
W. Ansorge, and S. A. Courtneidge.
1993.
The Src family tyrosine kinases are required for platelet-derived growth factor-mediated signal transduction in NIH 3T3 cells.
Proc. Natl. Acad. Sci. USA
90:7696-7700 |
| 122. | Umbhauer, M., C. J. Marshall, C. S. Mason, R. W. Old, and J. C. Smith. 1995. Mesoderm induction in Xenopus caused by activation of MAP kinase. Nature 376:58-62[Medline]. |
| 123. | Vojtek, A. B., S. M. Hollenberg, and J. A. Cooper. 1993. Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell 74:205-214[Medline]. |
| 124. | Warne, P. H., P. R. Viciana, and J. Downward. 1993. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature 364:352-355[Medline]. |
| 125. | Williams, N. G., and T. M. Roberts. 1994. Signal transduction pathways involving the Raf proto-oncogene. Cancer Metastasis Rev. 13:105-116[Medline]. |
| 126. |
Williams, N. G.,
T. M. Roberts, and P. Li.
1992.
Both p21ras and pp60v-src are required, but neither alone is sufficient, to activate the Raf-1 kinase.
Proc. Natl. Acad. Sci. USA
89:2922-2926 |
| 127. | Williams, S. A., E. R. Gillan, E. Knoppel, J. S. Buzby, Y. Suen, and M. S. Cairo. 1997. Effects of phosphodiester and phosphorothioate antisense oligodeoxynucleotides on cell lines which overexpress c-myc: implications for the treatment of Burkitt's lymphoma. Ann. Oncol. 8(Suppl.):25-30. |
| 128. | Woods, D., D. Parry, H. Cherwinski, E. Bosch, E. Lees, and M. McMahon. 1997. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol. Cell. Biol. 17:5598-5611[Abstract]. |
| 129. |
Wrighton, C., and M. Busslinger.
1993.
Direct transcriptional stimulation of the ornithine decarboxylase gene by Fos in PC12 cells but not in fibroblasts.
Mol. Cell. Biol.
13:4657-4669 |
| 130. |
Xia, K.,
N. K. Mukhopadhyay,
R. C. Inhorn,
D. L. Barber,
P. E. Rose,
R. S. Lee,
R. P. Narsimhan,
A. D. D'Andrea,
J. D. Griffin, and T. M. Roberts.
1996.
The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner.
Proc. Natl. Acad. Sci. USA
93:11681-11686 |
| 131. |
Xie, W., and H. R. Herschman.
1995.
v-src induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor.
J. Biol. Chem.
270:27622-27628 |
| 132. |
Yamauchi, N.,
A. A. Kiessling, and G. M. Cooper.
1994.
The Ras/Raf signaling pathway is required for progression of mouse embryos through the two-cell stage.
Mol. Cell. Biol.
14:6655-6662 |
| 133. |
Yancopoulos, G. D.,
P. D. Nisen,
A. Tesfaye,
N. E. Kohl,
M. P. Goldfarb, and F. W. Alt.
1985.
N-myc can cooperate with ras to transform normal cells in culture.
Proc. Natl. Acad. Sci. USA
82:5455-5459 |
| 134. | Yang, B. S., C. A. Hauser, G. Henkel, M. S. Colman, C. Van Beveren, K. J. Stacey, D. A. Hume, R. A. Maki, and M. C. Ostrowski. 1996. Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Mol. Cell. Biol. 16:538-547[Abstract]. |
| 135. | Yao, B., Y. Zhang, S. Delikat, S. Mathias, S. Basu, and R. Kolesnick. 1995. Phosphorylation of Raf by ceramide-activated protein kinase. Nature 378:307-310[Medline]. |
| 136. | Zornig, M., and G. I. Evan. 1996. Cell cycle: on target with Myc. Curr. Biol. 6:1553-1556[Medline]. |
| 137. |
Zou, X.,
S. Rudchenko,
K. Wong, and K. Calame.
1997.
Induction of c-myc transcription by the v-Abl tyrosine kinase requires Ras, Raf1, and cyclin-dependent kinases.
Genes Dev.
11:654-662 |
Molecular and Cellular Biology, February 1999, p. 1101-1115, Vol. 19, No. 2
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Rovida, E., Spinelli, E., Sdelci, S., Barbetti, V., Morandi, A., Giuntoli, S., Dello Sbarba, P.
(2008). ERK5/BMK1 Is Indispensable for Optimal Colony-Stimulating Factor 1 (CSF-1)-Induced Proliferation in Macrophages in a Src-Dependent Fashion. J. Immunol.
180: 4166-4172
[Abstract] [Full Text] -
Takeshita, S., Faccio, R., Chappel, J., Zheng, L., Feng, X., Weber, J. D., Teitelbaum, S. L., Ross, F. P.
(2007). c-Fms Tyrosine 559 Is a Major Mediator of M-CSF-induced Proliferation of Primary Macrophages. J. Biol. Chem.
282: 18980-18990
[Abstract] [Full Text] -
Cheng, Y., Chaturvedi, R., Asim, M., Bussiere, F. I., Xu, H., Casero, R. A. Jr., Wilson, K. T.
(2005). Helicobacter pylori-induced Macrophage Apoptosis Requires Activation of Ornithine Decarboxylase by c-Myc. J. Biol. Chem.
280: 22492-22496
[Abstract] [Full Text] -
Mirza, A. M., Gysin, S., Malek, N., Nakayama, K.-i., Roberts, J. M., McMahon, M.
(2004). Cooperative Regulation of the Cell Division Cycle by the Protein Kinases RAF and AKT. Mol. Cell. Biol.
24: 10868-10881
[Abstract] [Full Text] -
Ishibashi, M., McMahon, A. P.
(2003). A sonic hedgehog-dependent signaling relay regulates growth of diencephalic and mesencephalic primordia in the early mouse embryo. Development
129: 4807-4819
[Abstract] [Full Text] -
Weng, Z., Xin, M., Pablo, L., Grueneberg, D., Hagel, M., Bain, G., Muller, T., Papkoff, J.
(2002). Protection against Anoikis and Down-regulation of Cadherin Expression by a Regulatable beta -Catenin Protein. J. Biol. Chem.
277: 18677-18686
[Abstract] [Full Text] -
Moon, J. J., Nelson, B. H.
(2001). Phosphatidylinositol 3-Kinase Potentiates, but Does Not Trigger, T Cell Proliferation Mediated by the IL-2 Receptor. J. Immunol.
167: 2714-2723
[Abstract] [Full Text] -
Carnesecchi, S., Schneider, Y., Ceraline, J., Duranton, B., Gosse, F., Seiler, N., Raul, F.
(2001). Geraniol, a Component of Plant Essential Oils, Inhibits Growth and Polyamine Biosynthesis in Human Colon Cancer Cells. J. Pharmacol. Exp. Ther.
298: 197-200
[Abstract] [Full Text] -
Bowman, T., Broome, M. A., Sinibaldi, D., Wharton, W., Pledger, W. J., Sedivy, J. M., Irby, R., Yeatman, T., Courtneidge, S. A., Jove, R.
(2001). Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc. Natl. Acad. Sci. USA
10.1073/pnas.131568898v1
[Abstract] [Full Text] -
Woods, D., Cherwinski, H., Venetsanakos, E., Bhat, A., Gysin, S., Humbert, M., Bray, P. F., Saylor, V. L., McMahon, M.
(2001). Induction of {beta}3-Integrin Gene Expression by Sustained Activation of the Ras-Regulated Raf-MEK-Extracellular Signal-Regulated Kinase Signaling Pathway. Mol. Cell. Biol.
21: 3192-3205
[Abstract] [Full Text] -
Rovida, E., Marra, F., Baccarini, M., Sbarba, P. D.
(2000). Constitutive activation of the MAPK pathway mediates v-fes-induced mitogenesis in murine macrophages. Blood
95: 3959-3963
[Abstract] [Full Text] -
Mirza, A. M., Kohn, A. D., Roth, R. A., McMahon, M.
(2000). Oncogenic Transformation of Cells by a Conditionally Active Form of the Protein Kinase Akt/PKB. Cell Growth Differ.
11: 279-292
[Abstract] [Full Text] -
Park, J.-S., Boyer, S., Mitchell, K., Gilfor, D., Birrer, M., Darlington, G., El Deiry, W., Firestone, G. L., Munger, K., Band, V., Fisher, P. B., Dent, P.
(2000). Expression of Human Papilloma Virus E7 Protein Causes Apoptosis and Inhibits DNA Synthesis in Primary Hepatocytes via Increased Expression of p21Cip-1/WAF1/MDA6. J. Biol. Chem.
275: 18-28
[Abstract] [Full Text] -
Jaworowski, A., Wilson, N. J., Christy, E., Byrne, R., Hamilton, J. A.
(1999). Roles of the Mitogen-activated Protein Kinase Family in Macrophage Responses to Colony Stimulating Factor-1 Addition and Withdrawal. J. Biol. Chem.
274: 15127-15133
[Abstract] [Full Text] -
Bowman, T., Broome, M. A., Sinibaldi, D., Wharton, W., Pledger, W. J., Sedivy, J. M., Irby, R., Yeatman, T., Courtneidge, S. A., Jove, R.
(2001). Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc. Natl. Acad. Sci. USA
98: 7319-7324
[Abstract] [Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»